Single low-dose VSV-EBOV vaccination protects cynomolgus macaques from lethal Ebola challenge
Open Access
- 1 November 2019
- journal article
- research article
- Published by Elsevier in EBioMedicine
- Vol. 49, 223-231
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- VSVΔG/EBOV GP-Induced Innate Protection Enhances Natural Killer Cell Activity to Increase Survival in a Lethal Mouse Adapted Ebola Virus InfectionViral Immunology, 2015
- Emergence of Zaire Ebola Virus Disease in GuineaNew England Journal of Medicine, 2014
- Antibodies are necessary for rVSV/ZEBOV-GP–mediated protection against lethal Ebola virus challenge in nonhuman primatesProceedings of the National Academy of Sciences, 2013
- Vesicular Stomatitis Virus–Based Ebola Vaccines With Improved Cross-Protective EfficacyThe Journal of Infectious Diseases, 2011
- Impact of Ebola Mucin-Like Domain on Antiglycoprotein Antibody Responses Induced by Ebola Virus-Like ParticlesThe Journal of Infectious Diseases, 2011
- Single-Injection Vaccine Protects Nonhuman Primates against Infection with Marburg Virus and Three Species of Ebola VirusJournal of Virology, 2009
- Structure of the Ebola virus glycoprotein bound to an antibody from a human survivorNature, 2008
- Assessment of a Vesicular Stomatitis Virus–Based Vaccine by Use of the Mouse Model of Ebola Virus Hemorrhagic FeverThe Journal of Infectious Diseases, 2007
- Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg virusesNature Medicine, 2005
- Properties of Replication-Competent Vesicular Stomatitis Virus Vectors Expressing Glycoproteins of Filoviruses and ArenavirusesJournal of Virology, 2004